ABSTRACT
ABSTRACT Introduction: Cherry extract has a high amount of anthocyanins and flavonoids containing antioxidant effects. Its high antioxidant characteristics have been shown to reduce markers of delayed muscle soreness (DOMS) and exercise-induced muscle damage (EIMD) to improve recovery after exercise. Objective: Verify the effects of the cherry extract on post-exercise muscle damage. Methods: Google scholar, Medline, and Scopus were systematically searched until February 2022. The Cochrane Collaboration tool was applied to determine the risks of bias. Results: The results showed that cherry extract administration did not have a decreasing impact on creatine kinase levels overall: (WMD = 12.85 IU. L-1, 95% CI: −35.94, 61.64; P = 0.606). Considerable heterogeneity was observed among the articles (Cochran's Q-test = 990.80, P = 0.000, I2 = 96.7 %). However, there is a significant reducing effect on pain sensation by the consumption of cherry extract (WMD = −6.105 mm; 95% CI: −11.193 −1.017; p = 0.019). Conclusion: Cherry extract consumption effectively reduced late-onset muscle pain among participants in the overall and subgroup analysis. Thus, the cherry extract may be a complementary alternative in recovery after exercise. Level of evidence II; Therapeutic studies - Manuscript review.
RESUMO Introdução: O extrato de cereja tem uma alta quantidade de antocianinas e flavonóides contendo efeitos antioxidantes. Suas altas características antioxidantes demonstraram reduzir os marcadores de dor muscular retardada (DOMS) e dano muscular induzido pelo exercício (EIMD) para melhorar a recuperação após o exercício. Objetivo: Verificar os efeitos do extrato de cereja nos danos musculares pós-exercício. Métodos: Google scholar, Medline e Scopus foram sistematicamente pesquisados até fevereiro de 2022. A ferramenta de colaboração da Cochrane foi aplicada para determinar os riscos de viés. Resultados: Os resultados mostraram que a administração do extrato de cereja não teve um impacto decrescente nos níveis de creatina quinase em geral: (WMD = 12,85 IU. L-1, 95% CI: −35,94, 61,64; P = 0,606). Uma heterogeneidade considerável foi observada entre os artigos (teste Q da Cochran = 990,80, P = 0,000, I2 = 96,7 %). Porém, há um efeito redutor significativo na sensação de dor pelo consumo de extrato de cereja (WMD = −6,105 mm; 95% CI: −11,193 −1,017; p = 0,019). Conclusão: O consumo de extrato de cereja foi efetivo na redução de dores musculares de início tardio entre os participantes, na análise geral e nos subgrupos. Assim, o extrato de cereja pode ser uma alternativa complementar na recuperação após os exercícios. Nível de evidência II; Estudos terapêuticos - Revisão de manuscritos.
RESUMEN Introducción: El extracto de cereza tiene una gran cantidad de antocianinas y flavonoides con efectos antioxidantes. Se ha demostrado que sus altas características antioxidantes reducen los marcadores de dolor muscular retardado (DOMS) y el daño muscular inducido por el ejercicio (EIMD) para mejorar la recuperación después del ejercicio. Objetivo: Verificar los efectos del extracto de cereza en el daño muscular posterior al ejercicio. Métodos: Se realizaron búsquedas sistemáticas en Google scholar, Medline y Scopus hasta febrero de 2022. Se aplicó la herramienta de colaboración Cochrane para determinar los riesgos de sesgo. Resultados: Los resultados mostraron que la administración de extracto de cereza no tuvo un impacto decreciente en los niveles de creatina quinasa en general: (WMD = 12,85 UI. L-1, IC del 95%: −35,94, 61,64; P = 0,606). Se observó una considerable heterogeneidad entre los artículos (prueba Q de Cochran = 990,80, P = 0,000, I2 = 96,7 %). Sin embargo, el consumo de extracto de cereza tiene un efecto significativo de reducción del dolor (WMD = −6,105 mm; IC del 95%: −11,193 −1,017; p = 0,019). Conclusión: El consumo de extracto de cereza fue eficaz para reducir el dolor muscular de aparición tardía entre los participantes en el análisis global y de subgrupos. Así, el extracto de cereza puede ser una alternativa complementaria en la recuperación después de los ejercicios. Nivel de evidencia II; Estudios terapéuticos - Revisión de manuscritos.
ABSTRACT
@#Objective To compare the clinical efficacy of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) in patients with coronary heart disease and left ventricular systolic dysfunction. Methods A computer-based search in PubMed, The Cochrane Library and EMbase up to October 2017, together with reference screening, was performed to identify eligible clinical trials, cohort studies and case-control studies. The outcomes of this meta-analysis included all-cause mortality, myocardial infarction, revascularization and stroke, and the effect sizes for them were presented as relative risk (RR) with its 95% confidence intervals (CI). Results Fifteen cohort studies and 2 randomized controlled trials were finally included with a total of 11 985 patients, of whom 6 322 were in the CABG group and 5 663 in the PCI group. The result of meta-analysis showed that all-cause mortality was significantly lower in the CABG group than that in the PCI group (18.6% vs. 23.0%, RR=0.87, 95% CI 0.81 to 0.94, P<0.001). In addition, CABG was associated with a remarkably reduced risk of revascularization (RR=0.28, 95% CI 0.19 to 0.42, P<0.001) compared with PCI, with no significant difference in incidence of myocardial infarction (RR=0.78, 95% CI 0.47 to 1.32, P=0.36) and stroke (RR=1.28, 95% CI 0.89 to 1.86, P=0.18). Conclusion CABG is superior to PCI in the treatment for patients with coronary heart disease and left ventricular systolic dysfunction. Owing to the limited quality of included studies, additional large, randomized controlled trails are still required to confirm this finding.